A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2012
At a glance
- Drugs Evacetrapib; Ketoconazole
- Indications Atherosclerosis; Dyslipidaemias
- Focus Adverse reactions; Pharmacokinetics
- 21 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 11 Oct 2011 New trial record